New drug offers hope for severe cedar allergy sufferers
NCT ID NCT03369704
First seen Jan 12, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tested whether adding omalizumab to standard allergy medications (antihistamines and nasal sprays) could better control symptoms in 337 adults and teens with severe Japanese cedar pollinosis. Participants had severe symptoms despite current treatments. The study compared omalizumab to a placebo over 12 weeks during pollen season, measuring nasal and eye symptom scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEASONAL ALLERGIC RHINITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Chiba, Chiba, 262-0015, Japan
-
Novartis Investigative Site
Ichikawa, Chiba, 272-0143, Japan
-
Novartis Investigative Site
Kashiwa, Chiba, 2270082, Japan
-
Novartis Investigative Site
Matsudo, Chiba, 270-0034, Japan
-
Novartis Investigative Site
Matsudo, Chiba, 2710077, Japan
-
Novartis Investigative Site
Urayasu, Chiba, 279-0012, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 212-0027, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216 0006, Japan
-
Novartis Investigative Site
Kawasaki, Kanagawa, 216-0002, Japan
-
Novartis Investigative Site
Yokohama, Kanagawa, Japan
-
Novartis Investigative Site
Koshigaya, Saitama, 343-0031, Japan
-
Novartis Investigative Site
Arakawa-ku, Tokyo, 116 0011, Japan
-
Novartis Investigative Site
Chiyoda-ku, Tokyo, 101-0063, Japan
-
Novartis Investigative Site
Chuo Ku, Tokyo, 103 0027, Japan
-
Novartis Investigative Site
Edogawa-ku, Tokyo, 132-0014, Japan
-
Novartis Investigative Site
Katsushika-ku, Tokyo, 125-0061, Japan
-
Novartis Investigative Site
Nakano-ku, Tokyo, 164-0012, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 158-0097, Japan
-
Novartis Investigative Site
Shinjuku Ku, Tokyo, 160-0008, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, 160-0017, Japan
-
Novartis Investigative Site
Shinjuku-ku, Tokyo, Japan
-
Novartis Investigative Site
Toshima-Ku, Tokyo, 170-0005, Japan
Conditions
Explore the condition pages connected to this study.